drugset / Trial / NCT00490776
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
NaSingle-groupOpen-labelTreatment
Summary
This study evaluated the safety and efficacy of LBH589B in adult participants with refractory/resistant Cutaneous T-Cell Lymphoma and prior Histone Deacetylase (HDAC) inhibitor therapy.
Timeline
- Start
- 2007-07-05
- Primary completion
- 2009-09
- Completion
- 2009-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | 20 mg | Oral |